Enhancing Early Dementia Symptoms with Personalized Treatment Plans

Customized intervention plans that blend targeted medical strategies with lifestyle modifications have shown promising results in enhancing memory and cognitive functions among individuals with mild cognitive impairment and early-stage dementia. Assessments of factors affecting cognition, such as mold exposure, infections, or hormonal deficiencies, are crucial for developing these personalized plans.

Dementia encompasses various conditions impacting memory, thinking, and daily functioning. Currently, there is no cure for dementia, and treatment mainly focuses on symptom management. For Alzheimer’s disease, which affects about 60-70% of dementia cases, treatments like lecanemab aim to eliminate harmful protein plaques in the brain.

However, many experts indicate that these treatments may not effectively alleviate symptoms. The complexity of Alzheimer’s and other dementias may account for this, with growing evidence highlighting the role of age-related brain changes and various genetic, health, and lifestyle factors. “[Patients] didn’t experience improvement because the root causes were not addressed initially,” says Dr. Cat Topps from Bay Area Wellness in Walnut Creek, California.

Dr. Topps and her team are now exploring personalized treatment plans. “The strategy is to identify and eliminate factors harming the brain, then reintroduce essential nutrients, hormones, and activities that boost neuroplasticity,” explains Topps.

The research team enrolled 73 participants, averaging 65 years old, with mild cognitive impairment or early-stage dementia; some met both Alzheimer’s and mild cognitive impairment criteria. The team conducted thorough evaluations, including blood tests for Alzheimer’s biomarkers and assessments of inflammation, infections, and deficiencies related to hormones, nutrition, and microbiota. Using this data, they tailored treatment plans for 50 participants, emphasizing the inclusion of nutritional supplements.

Participants were encouraged to adopt a plant-rich diet, perform aerobic and strength training six days a week, and engage daily in cognitive activities targeting memory, attention, and visual processing speed. Additionally, strategies for improving sleep quality and managing stress were offered.

The remaining 23 participants followed standard treatment protocols. After nine months, those in the personalized intervention group saw a 13.7-point improvement in their overall cognitive scores on the Central Nervous System Vital Signs cognitive test, compared to a 4.5-point decline in the standard treatment group. Specific improvements included a 10.6-point increase in memory, a 9.8-point rise in executive function, and a 6.9-point boost in processing speed. “Over 90% of patients utilizing the precision medicine approach demonstrated statistically significant improvements,” noted Dr. Toups.

Researchers, including Anna Doherty from Wayne State University, find the results promising, supporting ongoing efforts to address cognitive decline through tailored strategies. “Precision medicine can integrate various health and genetic risks alongside identified lifestyle resilience factors,” she stated. Nevertheless, larger studies are required to validate these findings.

Previous research on personalized medicine has primarily relied on case reports, with limited data from randomized controlled trials. “This trial provides the most robust evidence to date,” remarked Christine Glorioso from NeuroAge Therapeutics.

Despite this, biomarker assessments and brain scans showed no significant changes from the study’s onset to conclusion in either group. According to Andrew Cermak, an independent imaging scientist, measuring the impact of interventions on symptoms can be challenging, especially in small cohorts over short durations. “Often, improvements may reflect changes in functional or cognitive measures rather than an actual correction of underlying neurodegenerative processes,” he explained.

It remains uncertain how much the benefits from personalized interventions outweigh the effects of lifestyle changes like regular exercise and cognitive training, both of which have consistently shown a reduced risk of dementia. “It’s complicated to isolate individual contributions when interventions are combined and personalized,” he added. Dr. Thomas Holland from Rush University stated, “Generally, the cumulative impact is likely the most significant factor.”

Glorioso suggested that future trials might need to clarify specific intervention aspects, such as whether participants received a supplement or placebo. “Given the open-label study design and largely negative biomarker findings, crucial questions about the interventions remain unanswered,” she emphasized.

Nonetheless, Dr. Toups advocates for swift implementation of personalized interventions, highlighting that the control group received these tailored approaches after a six-month delay, which may have hampered their progress. “There’s no time to waste when brain degeneration is involved,” she concluded.